# NASH - Nonalcoholic Steatohepatitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis

> 2 upcoming FDA catalysts in NASH - Nonalcoholic Steatohepatitis: Rezdiffra (resmetirom, MDGL) on January 2028 (primary completion); Rezdiffra (resmetirom, MDGL) on Jan to Apr 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 29, 2026 | [Lanifibranor primary completion](https://sec-api.dev/pdufa/lanifibranor) | IVA | NASH - Nonalcoholic Steatohepatitis | completed | "NCT04849728 (A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-09-29 (ACTUAL); Lead Sponsor Inventiva Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04849728)) |
| January 2028 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH - Nonalcoholic Steatohepatitis | scheduled | "NCT03900429 (A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03900429)) |
| Jan to Apr 2028 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH - Nonalcoholic Steatohepatitis | scheduled | "NCT03900429 (A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03900429)) |

## Drugs

- [Lanifibranor](https://sec-api.dev/pdufa/lanifibranor) (IVA)
- [Rezdiffra (resmetirom)](https://sec-api.dev/pdufa/resmetirom) (MDGL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NASH - Nonalcoholic Steatohepatitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis

```bibtex
@misc{secapidev_indications_nash_nonalcoholic_steatohepatitis_20261116,
  title        = {NASH - Nonalcoholic Steatohepatitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_nash_nonalcoholic_steatohepatitis_20261116","title":"NASH - Nonalcoholic Steatohepatitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/nash-nonalcoholic-steatohepatitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
